The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMPN 2026 | Promising advances and remaining challenges in MDS/MPN overlaps
Abdulraheem Yacoub, MD, University of Kansas Medical Center, Kansas City, KS, discusses advances in understanding myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) overlaps, highlighting progress in developing concrete diagnostic criteria and molecular definitions that enable biology-driven therapies and study designs. Dr Yacoub notes that while designing prospective and randomized studies in these patients is challenging, it has not hindered efforts to gather more data. This interview took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, D.C.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
